Research programme: antibody therapeutics - Adimab/Human Genome Sciences

Drug Profile

Research programme: antibody therapeutics - Adimab/Human Genome Sciences

Latest Information Update: 06 Aug 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Adimab; Human Genome Sciences
  • Class Antibodies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Research Unspecified

Most Recent Events

  • 03 Aug 2012 Human Genome Sciences has been acquired by GlaxoSmithKline
  • 30 Aug 2011 Early research is ongoing in USA
  • 16 Dec 2010 Early research in Undefined indication in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top